From May 13 to 17, 2025, local time, this year's annual meeting of the American Society of Gene and Cell Therapy (ASGCT) will be held in New Orleans, Louisiana, USA. The abstracts of the annual meeting were officially released by ASGCT on April 29, 2025. Grail Bio will share its research findings on the next-generation tumor neoantigen vaccine project, which utilizes a combined antigen-presenting cell (APC) targeted delivery platform, through an oral presentation to exchange insights with industry experts from around the world.Title:APC-Targeted LNP Enables Systemic Delivery of Neoantigen mRNA Vaccines and Enhanced Antigen-Specific T Cell Responses
Display Time:2025Year5Month15Day (Thursday)5:15 PM – 5:30 PM (Local time)
Oral Presenter:Chief Scientific Officer of Grail Bio, Professor Wang Pin
Display Area:Room 288-290
Report Highlights:
Grit Bio collaborates with Tianze Cloud to pioneer a new generation of mRNA tumor vaccine delivery system, which can selectively and precisely target antigen-presenting cells (APCs) throughout the body, significantly enhancing immune response while reducing toxicity. The research team has developed a novel APC-targeting lipid nanoparticle (APC-LNP) delivery system that achieves efficient and specific transfection of APCs under intravenous administration, with minimal impact on liver and lung parenchymal cells.
Preclinical studies show that the dose of APC-LNP required to induce an equally potent antigen-specific T-cell response is only one-tenth of the LPX (lipoplex, a systemic APC-targeting delivery system developed by BioNTech and already in clinical use), and APC-LNP can induce long-lasting memory responses favorable for vaccines.
Animal model data further indicates that the platform has good clinical application potential. NEOvigator™, a neoantigen discovery and prediction platform independently developed by Gracell Biotechnologies, integrates artificial intelligence and machine learning algorithms to successfully predict 20 highly immunogenic tumor neoantigens in mouse tumors. The neoantigen tumor vaccine prepared via APC-LNP/mRNA packaging achieved complete tumor suppression in a CT26 lung metastasis model and effectively prevented recurrence upon tumor re-challenge. Moreover, the neoantigen tumor vaccine also demonstrated significant efficacy in the highly malignant B16-F10 melanoma model. Preclinical safety study results obtained from multiple animal models confirmed that the system has excellent in vivo tolerance. Currently, GT601, a neoantigen tumor vaccine pipeline developed by Gracell Biotechnologies, is undergoing investigator-initiated clinical trials in China.IIT) Evaluation.'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Grit Bio was founded in 2019 as an innovative pharmaceutical company focused on tumor immunotherapy, with a research and development pipeline represented by TIL drugs. Grit Bio has completed multiple rounds of equity financing, receiving support from several well-known venture capital funds both in China and internationally. GT101 Injection, independently developed by Grit Bio, is the first TIL drug in China to be approved for clinical trials, and it has now entered a pivotal Phase II clinical trial. The company’s core R&D platforms include the StemTexp® Stem-like TIL Expansion Technology Platform, StaViral® Stable Viral Production System, ImmuT Finder® Immunomodulatory Target Discovery Platform, and KOReTIL® High-efficiency Gene Knockout System, based on which a series of next-generation gene-edited TIL drugs are being developed. Grit Bio possesses world-leading technological reserves and industrial resources, aiming to create groundbreaking cellular therapies for solid tumors, bringing new hope to cancer patients.AboutTianze CloudTech
Vitalgen was registered in Shanghai, China in March 2020. It is committed to transforming cutting-edge gene and cell therapy technologies into clinically accessible treatment methods with the aim of benefiting more patients. Vitalgen owns proprietary intellectual property rights over several platforms: the ViVec® AAV vector screening platform, the ViLNP® lipid nanoparticle technology platform, the ViCas® CRISPR gene editing technology platform, and the ViHiYi® AAV high-yield technology platform. Through strategies such as gene replacement, gene regulation, and gene editing, the company develops innovative gene therapies for central nervous system diseases, metabolic and hematological disorders, ophthalmic diseases, and cancer, boasting a diversified pipeline that includes multiple potential First-in-class products.
